Biological correlates of the congruence and incongruence of psychotic symptoms in patients with type 1 bipolar disorder

Neuropsychobiology

Volumn 58, Issue 3-4, 2008, Pages 111-117

  Basterreche, Nieves ^a   Dávila, Ricardo ^a,e   Zumárraga, Mercedes ^a   Arrúe, Aurora ^a   González Torres, Miguel Angel ^b   Zamalloa, María I ^a   Anguiano, Juan B ^c   Guimón, José ^d  

^a Hospital Psiquiátrico de Zamudio   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

^c Centro de Salud Mental de Ortuella   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e Hospital Psiquiatrico de Zamudio   (Spain)

Author keywords

3,4 Dihydroxyphenylacetic acid; 3 Methoxy 4 hydroxyphenylethylenglycol; Bipolar disorder; Catechol O methyl transferase; Congruent psychosis; Homovanillic acid; Incongruent psychosis

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CATECHOL METHYLTRANSFERASE; HOMOVANILLIC ACID;

ADULT; ARTICLE; BIPOLAR I DISORDER; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; NEUROCHEMISTRY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PSYCHOSIS;

3,4-DIHYDROXYPHENYLACETIC ACID; ADULT; BIPOLAR DISORDER; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENOTYPE; HOMOVANILLIC ACID; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; POLYMORPHISM, SINGLE NUCLEOTIDE; SOCIOECONOMIC FACTORS;

EID: 55449083719     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000170391     Document Type: Article

References (47)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorder (DSMIV-TR). Washington, American Psychiatric Association, 2000.
2. World Health Organization: Manual of the International Statistical Classification of Diseases, Injures and Causes of Death, revision 10 (ICD-10). Geneva, World Health Organization, 1992.
3. Fortunati F, Mazure C, Preda A, Wahl R, Bowers M Jr: Plasma catecholamine metabolites in antidepressant-exacerbated mania and psychosis. J Affect Disord 2002;68:331-334.
4. Yoshimura R, Nakano Y, Hori H, Ikenouchi A, Ueda N, Nakamura J: Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum Psychopharmacol 2006;21:433-438.
5. Chou JC, Czobor P, Tuma I, Charles O, Bebe R, Cooper TB, Chang WH, Lane HY, Stone DL: Pretreatment plasma HVA and haloperidol response in acute mania. J Affect Disord 2000;59:55-59.
6. Mazure CM, Bowers MB: Pretreatment plasma HVA predicts neuroleptic response in manic psychosis. J Affect Disord 1998;48:83-86.
7. Goes FS, Zandi PP, Miao K, McMahon FJ, Steele J, Willour VL, Mackinnon DF, Mondimore FM, Schweizer B, Nurnberger JI Jr, Rice JP, Scheftner W, Coryell W, Berrettini WH, Kelsoe JR, Byerley W, Murphy DL, Gershon ES, Bipolar Disorder Phenome Group, Depaulo JR Jr, McInnis MG, Potash JB: Mood-incongruent psychotic features in bipolar disorder: Familial aggregation and suggestive linkage to 2p11-q14 and 13q21-33. Am J Psychiatry 2007;164:236-247.
8. Faraone SV, Kremen WS, Tsuang MT: Genetic transmission of major affective disorders: quantitative models and linkage analyses. Psychol Bull 1990;108:109-127.
9. Anguelova M, Benkelfat C, Turecki G: A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter. I. Affective disorders. Mol Psychiatry 2003;8:574-591.
10. Badner JA, Gershon ES: Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002;7:405-411.
11. Crow TJ: How and why genetic linkage has not solved the problem of psychosis: review and hypothesis. Am J Psychiatry 2007;164:13-21.
12. Faraone SV, Lasky-Su J, Glatt SJ, Van Eerdewegh P, Tsuang MT: Early onset bipolar disorder: possible linkage to chromosome 9q34. Bipolar Disord 2006;8:144-151.
13. Bilder RM, Volavka J, Lachman HM, Grace AA: The catechol -O-methyltransferase polymorphism: relations to the tonicphasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004;29:1943-1961.
14. Glatt SJ, Faraone SV, Tsuang MT: Association between a functional catechol-O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am J Psychiatry 2003;160:469-476.
15. Shifman S, Bronstein M, Sternfeld M, Pisanté-Shalom A, Lev-Lehman E, Weizman A, Reznik I, Spivak B, Grisaru N, Karp L, Schiffer R, Kotler M, Strous RD, Swartz-Vanetik M, Knobler HY, Shinar SE, Beckmann JS, Yakir B, Risch N, Zak NB, Darvasi A: A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002;71:1296-1302.
16. Funke B, Malhotra AK, Finn CT, Plocik AM, Lake SL, Lencz T, DeRosse P, Kane JM, Kucherlapati R: COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct 2005;1:1-9.
17. Diaz-Asper CM, Goldberg TE, Kolachana BS, Straub RE, Egan MF, Weinberger DR: Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls. Biol Psychiatry 2008;63:72-79.
18. Xu H, Kellendonk CB, Simpson EH, Keilp JG, Bruder GE, Polan HJ, Kandel ER, Gilliam TC: DRD2 C957T polymorphism interacts with the COMT Val158Met polymorphism in human working memory ability. Schizophr Res 2007;90:104-107.
19. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorder (DSM-IV). Washington, American Psychiatric Association, 1994.
20. First MB, Spitzer RL, Williams JBW: Structured Clinical Interview for the Diagnostic and Statistical Manual IV. Washington, American Psychiatric Press, 1997.
21. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435.
22. Toni C, Perugi G, Mata B, Madaro D, Maremmani I, Akiskal HS: Is mood-incongruent manic psychosis a distinct subtype? Eur Arch Psychiatry Clin Neurosci 2001;251:12-17.
23. Dávila R: Plasma HVA, neuroleptics, and dopaminergic plasticity. Biol Psychiatry 1989;25:1-3.
24. Zumárraga M, Andia I, Bárcena B, Zamalloa MI, Dávila R: Liquid-chromatographic method for determination of homovanillic acid in plasma, with electrochemical detection. Clin Chem 1987;33:72-75.
25. Rotondo A, Mazzanti C, Dell'Osso L, Rucci P, Sullivan P, Bouanani S, Gonnelli C, Goldman D, Cassano GB: Catechol-O-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry 2002;159:23-29.
26. Rizzo V, Melzi d'Eril GV: Determination of free 3-methoxy-4- hydroxyphenylethyleneglycol in plasma and in cerebrospinal fluid by liquid chromatography with coulometric detection. Clin Chem 1987;33:844-845.
27. Zumárraga M, Andía I, Dávila R, Zamalloa MI: Homovanillic acid in plasma determined by HPLC with direct injection of plasma filtrates. Clin Chem 1994;40:2119-2120.
28. Zumárraga M, Andia I, Bárcena B, Dávila R: Determinación simultánea de dopamina y ácido 3,4 dihidroxifenilacético en orina por HPLC y detección amperométrica. Biométrica 1984;3:109-120.
29. Azorin JM, Akiskal H, Hantouche E: The mood-instability hypothesis in the origin of mood-congruent versus mood-incongruent psychotic distinction in mania: validation in a French national study of 1,090 patients. J Affect Disord 2006;96:215-223.
30. Keck PE Jr, McElroy SL, Havens JR, Altshuler LL, Nolen WA, Frye MA, Suppes T, Denicoff KD, Kupka R, Leverich GS, Rush AJ, Post RM: Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Compr Psychiatry 2003;44:263-269.
31. Goodwin FK, Jamison KR: Manic-depressive illness. New York, Oxford University Press, 1990.
32. Fenning S, Bromet EJ, Tanenberg KM: Mood-congruent versus mood-incongruent psychotic symptoms in first-admission patients with affective disorder. J Affect Disord 1996;37:23-29.
33. Tohen M, Zarate CA Jr, Hennen J, Khalsa HM, Strakowski SM, Gebre-Medhin P, Salvatore P, Baldessarini RJ: The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003;160:2099-2107.
34. Tohen M, Tsuang MT, Goodwin DC: Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features. Am J Psychiatry 1992;149:1580-1584.
35. Burch EA Jr, Anton RF, Carson WH: Mood congruent and incongruent psychotic depressions: are they the same? J Affect Disord 1994;31:275-280.
36. Gutiérrez B, Bertranpetit J, Guillamat R, Vallés V, Arranz MJ, Kerwin R, Fañanás L: Association analysis of the catechol-O-methyltransferase gene and bipolar affective disorder. Am J Psychiatry 1997;154:113-115.
37. Kunugi H, Vallada HP, Hoda F, Kirov G, Gill M, Aitchison KJ, Ball D, Arranz MJ, Murray RM, Collier DA: No evidence for an association of affective disorders with high- or low-activity allele of catechol -O-methyltransferase gene. Biol Psychiatry 1997;42:282-285.
38. Stefanis NC, Henquet C, Avramopoulos D, Smyrnis N, Evdokimidis I, Myin-Germeys I, Stefanis CN, Van Os J: COMT Val158Met moderation of stress-induced psychosis. Psychol Med 2007;37:1651-1656.
39. Dávila R, Manero E, Zumárraga M, Andia I, Schweitzer JW, Friedhoff AJ: Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 1988;45:564-567.
40. Green AI, Alam MY, Boshes RA, Waternaux C, Pappalardo KM, Fitzgibbon ME, Tsuang MT, Schildkraut JJ: Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res 1993;10:33-37.
41. Bowers MB Jr, Swigar ME, Jatlow PI, Hoffman FJ, Goicoechea N: Early neuroleptic response: clinical profiles and plasma catecholamine metabolites. J Clin Psychopharmacol 1987;7:83-86.
42. Bowers MB, Kantrowitz JT: Elevated plasma dopamine metabolites in cannabis psychosis. Am J Psychiatry 2007;164:1615-1616.
43. Dávila R, Zumárraga M, Basterreche N, Arrúe A, Anguiano JB: Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms. Psychiatr Res 2007;151:6.
44. Marcelis M, Suckling J, Hofman P, Woodruff P, Bullmore E, van Os J: Evidence that brain tissue volumes are associated with HVA reactivity to metabolic stress in schizophrenia. Schizophr Res 2006;86:45-53.
45. Kirsch P, Ronshausen S, Mier D, Gallhofer B: The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients. Pharmacopsychiatry 2007;40:196-198.
46. Bowers MB: Psychotic patients with increased plasma HVA and MHPG or increased HVA alone. Biol Psychiatry 1993;34:584-586.
47. Dávila R, Zumárraga M, Basterreche N, Arrúe A, Zamalloa MI, Anguiano JB: Influence of the catechol-o-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder - a preliminary report. J Affect Disord 2006;92:277-281.